Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Jazz Pharmaceuticals plc ( JAZZ ) Deutsche Bank 2026 Healthcare Summit September 16, 2026 8:00 AM EDT Company Participants Robert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & Development Conference Call Participants David Hoang - Deutsche Bank AG, Research Division Presentation Robert Iannone Executive VP, Chief Medical Officer and Global Head of Research & Development The potential synergy that you can get when using zanidatamab, a highly immune active antibody in conjunction with immune checkpoint inhibitor like tislelizumab. So really pleased with that. And on the heels of it, remember, we had static overall survival benefit for the triplet arm at the time of the first interim analysis with 2 additional scheduled OS analyses. And at that time, the Arm B or the doublet arm was trending very favorably, but not quite static. On the second interim analysis, we now have a static result for the zani chemo versus the control arm. And encouragingly, as we said in our press release, the hazard ratios for both of the experimental arms continue to improve even from the first interim analysis when you look at the overall survival, which is consistent with highly immune active drugs where you tend to see that benefit beyond the medians later on that curve, you see more durable benefit and you start to see the curve separate. We're excited to publish those data as soon as we can in an upcoming medical conference. Just quickly mention some other areas that we're leaning into on Ziihera. We have our frontline BTC trial, which is well underway. We have our late line pivotal trial. We have our late-line breast cancer pivotal trial that's well underway. We also have a pan-tumor trial that could get us a tumor-agnostic indication, meaning any patient whose tumor overexpresses HER2 and is refractory to standard therapies